Standout Papers

Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma 2021 2026 2022 2024241
  1. Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma (2021)
    Michael E. Wechsler, Marcella Ruddy et al. New England Journal of Medicine

Immediate Impact

2 by Nobel laureates 5 from Science/Nature 55 standout
Sub-graph 1 of 21

Citing Papers

Reteplase versus Alteplase for Acute Ischemic Stroke
2024 Standout
Type 2 chronic inflammatory diseases: targets, therapies and unmet needs
2023 Standout
1 intermediate paper

Works of Andreas Jessel being referenced

Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma
2021 Standout
Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK)
1994

Author Peers

Author Last Decade Papers Cites
Andreas Jessel 596 440 271 16 1.2k
Anjan Chakrabarti 433 240 159 22 934
Larry L. Shears 266 327 181 22 1.3k
Richard S. Pavelec 506 243 305 13 1.0k
Jacob Gurevitch 626 621 224 26 1.0k
J.F. Martin 551 251 177 32 1.3k
Vlasios Pyrgakis 733 239 166 35 1.3k
Neil K. Worrall 201 379 188 23 1.2k
Marc R. Litt 574 720 194 18 1.3k
Elizabeth N. Morgan 229 220 191 17 1.0k
Rosmarie Leiderer 203 514 183 18 1.3k

All Works

Loading papers...

Rankless by CCL
2026